Pharmacokinetic bioequivalence, safety, and immunogenicity of GB222, a bevacizumab biosimilar candidate, and bevacizumab in Chinese healthy males: a randomized clinical trial.
Dong W, Chen M, Niu S, Wang B, Xia L, Wang J, Shen T, Wang Q, Lv J, Liu G, Fan H, Xie Z, Xie F, An Y, Zheng Q, Rao H, Song H, Fang Y.
Dong W, et al. Among authors: shen t.
Expert Opin Biol Ther. 2022 Feb;22(2):253-262. doi: 10.1080/14712598.2021.1954157. Epub 2021 Jul 26.
Expert Opin Biol Ther. 2022.
PMID: 34236011
Clinical Trial.